Skip to Main Content

Editas Medicine announced the hiring of a new CEO on Thursday — the fourth top executive to lead the troubled maker of gene-editing treatments since 2014.

Gilmore O’Neill takes over as Editas’ CEO on June 1, the company said. He joins from Sarepta Therapeutics, where he served as chief medical officer.


O’Neill replaces Jim Mullen, the chair of Editas’ board who served as CEO for 14 months mostly because the company couldn’t find anyone else to take the job, multiple sources close to the company told STAT. Mullen will become executive chair of Editas following the transition.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.